Payment overview · 2025
General Payments
$459.32
17 reported records · 8 companies
Healthcare provider profile · identity verified
Joseph David Stokes, M.D.
Allopathic & Osteopathic Physicians|Family Medicine|Geriatric Medicine · NORTON, OH · NPI 1053396812
Verified facts
What the public records show
CMS Open Payments records show Joseph David Stokes, M.D. received $459.32 in general payments during 2025 across 17 reported records.
Gilead Sciences, Inc. accounted for 58.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Myrbetriq by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Jardiance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $270.61 | 58.9% | 7 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $50.52 | 11.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.08 | 8.1% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $33.70 | 7.3% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $19.14 | 4.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $18.93 | 4.1% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $15.29 | 3.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $14.05 | 3.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $459.32 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $50.52 | 2 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $37.08 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.70 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $21.87 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 2 Normalized: freestyle libre 2 |
Device | Abbott Laboratories | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $15.29 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $14.05 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
36 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 397 | 135 |
| Lisinopril | Lisinopril | 358 | 118 |
| Tramadol Hcl | Tramadol Hcl | 245 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 235 | 91 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 224 | 108 |
| Amlodipine Besylate | Amlodipine Besylate | 213 | 78 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 188 | 152 |
| Gabapentin | Gabapentin | 184 | 56 |
| Metformin Hcl | Metformin Hcl | 180 | 56 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 180 | 27 |
| Hydrochlorothiazide | Hydrochlorothiazide | 168 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 64 |
| Metoprolol Succinate | Metoprolol Succinate | 150 | 52 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 149 | 33 |
| Pantoprazole Sodium | Pantoprazole Sodium | 140 | 50 |
| Furosemide | Furosemide | 137 | 56 |
| Losartan Potassium | Losartan Potassium | 130 | 45 |
| Sertraline Hcl | Sertraline Hcl | 129 | 36 |
| Trazodone Hcl | Trazodone Hcl | 116 | 32 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 107 | 38 |
| Omeprazole | Omeprazole | 106 | 47 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 37 |
| Simvastatin | Simvastatin | 99 | 35 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 94 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 85 | 29 |
| Lorazepam | Lorazepam | 85 | 21 |
| Clonazepam | Clonazepam | 80 | 15 |
| Prednisone | Prednisone | 79 | 49 |
| Famotidine | Famotidine | 78 | 28 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 77 | 56 |
| Spironolactone | Spironolactone | 72 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 69 | suppressed |
| Carvedilol | Carvedilol | 68 | 21 |
| Diclofenac Sodium | Diclofenac Sodium | 66 | 29 |
| Doxycycline Hyclate | Doxycycline Hyclate | 65 | 52 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 60 | 16 |
| Alprazolam | Alprazolam | 58 | 13 |
| Escitalopram Oxalate | Escitalopram Oxalate | 58 | 18 |
| Pravastatin Sodium | Pravastatin Sodium | 57 | 21 |
| Warfarin Sodium | Warfarin Sodium | 57 | 14 |
| Allopurinol | Allopurinol | 56 | 21 |
| Donepezil Hcl | Donepezil Hcl | 56 | 16 |
| Paroxetine Hcl | Paroxetine Hcl | 54 | 13 |
| Glipizide | Glipizide | 53 | 22 |
| Torsemide | Torsemide | 53 | 20 |
| Finasteride | Finasteride | 51 | 21 |
| Montelukast Sodium | Montelukast Sodium | 50 | 17 |
| Duloxetine Hcl | Duloxetine Hcl | 48 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 48 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 46 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 12 |
| Pregabalin | Pregabalin | 42 | suppressed |
| Meloxicam | Meloxicam | 41 | 20 |
| Buspirone Hcl | Buspirone Hcl | 39 | 12 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Potassium Chloride | Potassium Chloride | 38 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | 16 |
| Symbicort | Budesonide/Formoterol Fumarate | 37 | suppressed |
| Eliquis | Apixaban | 36 | 16 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 32 | suppressed |
| Ibuprofen | Ibuprofen | 32 | 17 |
| Ondansetron Odt | Ondansetron | 32 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 32 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 31 | 12 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 30 | 12 |
| Atenolol | Atenolol | 27 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 27 | suppressed |
| Celecoxib | Celecoxib | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Azithromycin | Azithromycin | 24 | 20 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | 12 |
| Jantoven | Warfarin Sodium | 24 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | 15 |
| Promethazine Hcl | Promethazine Hcl | 24 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 24 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 23 | suppressed |
| Lovastatin | Lovastatin | 23 | suppressed |
| Ozempic | Semaglutide | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Bupropion Xl | Bupropion Hcl | 22 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 22 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 22 | suppressed |
| Gemfibrozil | Gemfibrozil | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 22 | suppressed |
| Verapamil Er | Verapamil Hcl | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 21 | suppressed |
| Methocarbamol | Methocarbamol | 21 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 20 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 20 | suppressed |
| Naproxen | Naproxen | 20 | 13 |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Nitroglycerin | Nitroglycerin | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 18 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | 12 |
| Linzess | Linaclotide | 17 | suppressed |
| Synthroid | Levothyroxine Sodium | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Diltiazem 12hr Er | Diltiazem Hcl | 16 | suppressed |
| Lidocaine | Lidocaine | 16 | suppressed |
| Myrbetriq | Mirabegron | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | 14 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 14 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 14 | suppressed |
| Nystatin | Nystatin | 14 | 11 |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Ezetimibe | Ezetimibe | 13 | suppressed |
| Lansoprazole | Lansoprazole | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 11 |
| Carisoprodol | Carisoprodol | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Jardiance | Empagliflozin | 12 | suppressed |
| Klor-Con M20 | Potassium Chloride | 12 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | suppressed |
| Ofloxacin | Ofloxacin | 12 | 12 |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Januvia | Sitagliptin Phosphate | 11 | suppressed |
| Nabumetone | Nabumetone | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Tradjenta | Linagliptin | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $459.32 · 17 records | Gilead Sciences, Inc. | FREESTYLE LIBRE 2, MOUNJARO, NURTEC ODT, QULIPTA, REPATHA, UBRELVY, Veozah, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error